Total Payments
$3.7M
2024 Payments
$505,814
Companies
107
Transactions
2,655
Medicare Patients
19,222
Medicare Billing
$1.6M
Payment Breakdown by Category
Consulting$2.6M (69.4%)
Other$591,741 (16.0%)
Research$267,417 (7.2%)
Travel$225,018 (6.1%)
Food & Beverage$43,819 (1.2%)
Education$6,043 (0.2%)
Gifts$581.25 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $2.6M | 583 | 69.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $493,063 | 190 | 13.3% |
| Unspecified | $267,417 | 433 | 7.2% |
| Travel and Lodging | $225,018 | 373 | 6.1% |
| Honoraria | $76,703 | 30 | 2.1% |
| Food and Beverage | $43,819 | 1,022 | 1.2% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $10,300 | 6 | 0.3% |
| Grant | $9,000 | 1 | 0.2% |
| Education | $6,043 | 13 | 0.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,500 | 1 | 0.1% |
| Gift | $581.25 | 1 | 0.0% |
| Debt forgiveness | $163.40 | 1 | 0.0% |
| Entertainment | $12.62 | 1 | 0.0% |
Payments by Type
General
$3.4M
2,222 transactions
Research
$267,417
428 transactions
Ownership
$0
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SN Holdings, LLC | $442,496 | 55 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $429,265 | 302 | $0 (2024) |
| PFIZER INC. | $408,028 | 321 | $0 (2024) |
| Photocure Inc | $237,634 | 28 | $0 (2024) |
| Merck Sharp & Dohme LLC | $200,791 | 128 | $0 (2024) |
| GENZYME CORPORATION | $161,005 | 93 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $142,496 | 71 | $0 (2024) |
| AstraZeneca UK Limited | $141,582 | 54 | $0 (2024) |
| Janssen Research & Development, LLC | $138,216 | 41 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $136,965 | 83 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $505,814 | 312 | Janssen Research & Development, LLC ($82,381) |
| 2023 | $780,503 | 350 | SN Holdings, LLC ($248,241) |
| 2022 | $412,175 | 288 | SN Holdings, LLC ($127,790) |
| 2021 | $326,746 | 290 | PFIZER INC. ($48,198) |
| 2020 | $440,353 | 293 | Merck Sharp & Dohme Corporation ($59,793) |
| 2019 | $479,198 | 428 | Ferring Pharmaceuticals Inc. ($69,015) |
| 2018 | $412,741 | 405 | Janssen Scientific Affairs, LLC ($68,573) |
| 2017 | $346,736 | 289 | Bayer HealthCare Pharmaceuticals Inc. ($61,024) |
All Payment Transactions
2,655 individual payment records from CMS Open Payments — Page 1 of 107
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $4,045.00 | General |
| Category: ONCOLOGY | ||||||
| 12/23/2024 | PFIZER INC. | XTANDI (Drug) | — | In-kind items and services | $780.00 | Research |
| Study: XTANDI CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 12/23/2024 | PFIZER INC. | XTANDI (Drug) | — | In-kind items and services | $780.00 | Research |
| Study: XTANDI CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 12/20/2024 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: TALZENNA CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 12/19/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug), ILLUCCIX | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| Category: PROSTATE CANCER THERAPY | ||||||
| 12/18/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,937.50 | General |
| 12/16/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $13.83 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/16/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $6.27 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $21.78 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 12/03/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $17.29 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Janssen Scientific Affairs, LLC | ERLEADA (Drug) | Consulting Fee | Cash or cash equivalent | $7,750.00 | General |
| Category: Oncology | ||||||
| 11/28/2024 | Novartis Pharma AG | PLUVICTO (Drug), LOCAMETZ | — | In-kind items and services | $1,275.59 | Research |
| Study: CAAA617B12302 • Category: ONCOLOGY | ||||||
| 11/26/2024 | PFIZER INC. | XTANDI (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: XTANDI CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 11/26/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $997.50 | General |
| 11/25/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $7,750.00 | General |
| 11/25/2024 | Blue Earth Diagnostics Limited | POSLUMA (Drug) | Food and Beverage | In-kind items and services | $24.38 | General |
| Category: Diagnostic Imaging | ||||||
| 11/22/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $29.63 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 11/22/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $3.92 | General |
| Category: Oncology | ||||||
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $22.58 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Consulting Fee | Cash or cash equivalent | $4,800.00 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $10,075.00 | General |
| 11/14/2024 | PFIZER INC. | — | — | In-kind items and services | $330.00 | Research |
| Study: NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | ||||||
| 11/13/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: Oncology | ||||||
| 11/12/2024 | PFIZER INC. | TALZENNA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,400.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TALAZOPARIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $55,530 | 44 |
| ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $40,730 | 43 |
| Neal Shore Oncology Projects | Janssen Scientific Affairs, LLC | $29,315 | 6 |
| XTANDI CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $20,990 | 17 |
| A MULTINATIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY ADT VERSUS PLACEBO PLUS ADT IN PATIENTS WITH METASTATIC HORMONE SENSITIVE PROSTATE CANCER MHSPC | Astellas Pharma Global Development | $14,069 | 50 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | Novartis Pharmaceuticals Corporation | $9,977 | 2 |
| A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | Astellas Pharma Global Development | $8,898 | 47 |
| TALZENNA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $7,620 | 7 |
| A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | Astellas Pharma Global Development | $7,311 | 29 |
| A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT) | Astellas Pharma Global Development | $7,235 | 22 |
| RELUGOLIX CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $6,400 | 2 |
| Research Publication/ Writing Support | Novartis Pharmaceuticals Corporation | $6,335 | 1 |
| A Multinational Phase 3 Randomized Double-blind Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | Astellas Pharma Global Development | $6,251 | 39 |
| A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer | Astellas Pharma Global Development | $5,059 | 2 |
| Review Article | Novartis Pharmaceuticals Corporation | $4,853 | 1 |
| SASANLIMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,470 | 3 |
| ONCOLOGY CROSS PORTFOLIO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,640 | 2 |
| The impact of bone-targeted therapies in patients with chemotherapy-nave metastatic castration-resistant prostate cancer on enzalutamide a post hoc analysis of PREVAIL | Astellas Pharma Global Development | $3,312 | 9 |
| Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) | Astellas Pharma Global Development | $2,770 | 12 |
| CAAA617B12302 | Novartis Pharma AG | $1,994 | 3 |
| A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 (ASP9785) vs. Bicalutamide in Castrate Men with Metastatic Prostate Cancer | Astellas Pharma Global Development | $1,932 | 3 |
| A PHASE 2 OPEN-LABEL EXTENSION STUDY TO ASSESS THE SAFETY OF CONTINUED ADMINISTRATION OF MDV3100 IN SUBJECTS WITH PROSTATE CANCER WHO SHOWED BENEFIT FROM PRIOR EXPOSURE TO MDV3100 | Astellas Pharma Global Development | $1,881 | 9 |
| A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy ADT Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer mHSPC | Astellas Pharma Global Development | $1,873 | 8 |
| PROSPER A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED S | Astellas Pharma Global Development | $1,757 | 12 |
| Observational cohort study of patients with Castration-Resistant Prostate Cancer (CRPC) (TRUMPET) | Astellas Pharma Global Development | $1,700 | 4 |
| A Phase 2 Open-label Extension Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100 | Astellas Pharma Global Development | $1,660 | 1 |
| Impact of bone-targeted therapies in patients with chemotherapy-nave metastatic castration-resistant prostate cancer on enzalutamide a post hoc analysis of PREVAIL | Astellas Pharma Global Development | $1,286 | 2 |
| AB -1179532023 - Patient Characteristics, Treatment Patterns and Outcomes among Early Adopters of Lutetium Lu 177 Vipivotide Tetraxetan (177 Lu-PSMA-617): A Real-World United States (US) Study. | Novartis Pharmaceuticals Corporation | $1,188 | 1 |
| ELRANATAMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| A Prospective Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) in the United States | Astellas Pharma Global Development | $784.00 | 2 |
| PROSPER A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO PBO-CONTRO | Astellas Pharma Global Development | $589.00 | 7 |
| Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer PROSPER | Astellas Pharma Global Development | $416.00 | 8 |
| Strive: A Multicenter Phase 2, Randomized, Double-blind, Efficacy And Safety Study Of Enzalutamide Vs. Bicalutamide In Men With Prostate Cancer Who Have Failed Primary Androgen Deprivation Therapy | Astellas Pharma Global Development | $415.00 | 2 |
| Fatigue in men with castration-resistant prostate cancer treated with enzalutamide a post hoc analysis of randomised clinical trials data | Astellas Pharma Global Development | $387.00 | 1 |
| FY22-6361 | Astellas Pharma Global Development | $365.52 | 1 |
| NIROGACESTAT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| RN888 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| TRUMPET | Astellas Pharma Global Development | $299.06 | 1 |
| PROSPER PROSTATE-SPECIFIC ANTIGEN PSA RESPONSE IN MEN WITH NON- | Astellas Pharma Global Development | $287.00 | 2 |
| None | Astellas Pharma Global Development | $278.00 | 1 |
| The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups | Astellas Pharma Global Development | $273.53 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PHASE II, EFFICACY AND SAFETY STUDY OF MDV3100 ASP9785 VS. BICALUTAMIDE IN CASTRATE MEN WITH METASTATIC PROSTATE CANCER | Astellas Pharma Global Development | $267.00 | 3 |
| A DOUBLE-BLINDED, PLACEBO-CONTROLLED, RANDOMIZED PHASE II STUDY OF ENZALUTAMIDE WITH OR WITHOUT THE PI3 KINASE-MTOR INHIBITOR LY3023414 IN MEN WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER | Eli Lilly and Company | $180.80 | 2 |
| PROSPER A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Enzalutamide in Men With Nonmetastatic Castration-Resistant Prostate Cancer | Astellas Pharma Global Development | $173.00 | 1 |
| PROSPER EINE RANDOMISIERTE, DOPPELBLINDE, PLACEBOKONTROLLIERTE PH | Astellas Pharma Global Development | $169.00 | 2 |
| PROSPER A PHASE 3 STUDY OF ENZALUTAMIDE ENZA IN MEN WITH NON-ME | Astellas Pharma Global Development | $159.00 | 1 |
| PROSPER Prostate-specific antigen PSA response in men with non-metastatic castration-resistant prostate cancer nmCRPC treated with enzalutamide ENZA results from PROSPER | Astellas Pharma Global Development | $43.00 | 1 |
| PROSPER a Phase 3, randomized, double-blind, placebo-controlled study of enzalutamide in men with non-metastatic castration-resistant prostate cancer | Astellas Pharma Global Development | $43.00 | 1 |
| PROSPER A MULTINATIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER | Astellas Pharma Global Development | $25.00 | 3 |
| PROSPER A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED | Astellas Pharma Global Development | $16.00 | 1 |
| A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure | Astellas Pharma Global Development | $8.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 33 | 3,743 | 17,637 | $930,508 | $292,332 |
| 2022 | 38 | 4,489 | 21,756 | $1.1M | $314,361 |
| 2021 | 53 | 5,421 | 30,186 | $1.6M | $480,544 |
| 2020 | 51 | 5,569 | 35,325 | $1.9M | $527,159 |
Total Patients
19,222
Total Services
104,904
Medicare Billing
$1.6M
Procedure Codes
176
All Medicare Procedures & Services
176 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 385 | 885 | $225,985 | $78,413 | 34.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 22 | 3,000 | $112,560 | $55,381 | 49.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 457 | 711 | $122,249 | $42,450 | 34.7% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 33 | 155 | $105,859 | $20,490 | 19.4% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2023 | 455 | 740 | $49,809 | $13,335 | 26.8% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2023 | 65 | 80 | $50,407 | $13,265 | 26.3% |
| J9155 | Injection, degarelix, 1 mg | Office | 2023 | 18 | 3,280 | $22,337 | $10,292 | 46.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 210 | 262 | $26,983 | $9,841 | 36.5% |
| 74178 | Ct scan of abdomen and pelvis before and after contrast | Office | 2023 | 39 | 39 | $32,061 | $7,065 | 22.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 501 | 674 | $10,514 | $5,646 | 53.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 26 | 30 | $10,312 | $3,996 | 38.8% |
| 81001 | Manual urinalysis test with examination using microscope, automated | Office | 2023 | 628 | 1,245 | $14,367 | $3,843 | 26.7% |
| 80048 | Blood test, basic group of blood chemicals (calcium, total) | Office | 2023 | 177 | 396 | $14,608 | $3,283 | 22.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 30 | 30 | $11,780 | $3,271 | 27.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 15 | 33 | $30,386 | $2,929 | 9.6% |
| 80076 | Liver function blood test panel | Office | 2023 | 154 | 360 | $10,753 | $2,884 | 26.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 150 | 306 | $8,299 | $2,329 | 28.1% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 49 | 83 | $7,223 | $1,885 | 26.1% |
| 51720 | Instillation of anti-cancer drug into bladder | Office | 2023 | 16 | 30 | $8,595 | $1,817 | 21.1% |
| 74170 | Ct scan of abdomen before and after contrast | Office | 2023 | 13 | 13 | $10,928 | $1,669 | 15.3% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Office | 2023 | 20 | 22 | $11,452 | $1,610 | 14.1% |
| 53899 | Other procedure on urinary system | Office | 2023 | 12 | 12 | $9,360 | $1,609 | 17.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 19 | 19 | $4,846 | $1,400 | 28.9% |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | Office | 2023 | 40 | 40 | $2,692 | $756.80 | 28.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 41 | 66 | $3,794 | $651.62 | 17.2% |
About Neal Shore, DR
Neal Shore, DR is a Urology healthcare provider based in Myrtle Beach, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/04/2005. The National Provider Identifier (NPI) number assigned to this provider is 1265423453.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Neal Shore, DR has received a total of $3.7M in payments from pharmaceutical and medical device companies, with $505,814 received in 2024. These payments were reported across 2,655 transactions from 107 companies. The most common payment nature is "Consulting Fee" ($2.6M).
As a Medicare-enrolled provider, Shore has provided services to 19,222 Medicare beneficiaries, totaling 104,904 services with total Medicare billing of $1.6M. Data is available for 4 years (2020–2023), covering 176 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Location Myrtle Beach, SC
- Active Since 11/04/2005
- Last Updated 12/29/2016
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1265423453
Products in Payments
- XTANDI (Drug) $209,222
- CYSVIEW (Drug) $193,489
- Nubeqa (Drug) $176,079
- JEVTANA (Drug) $145,096
- LYNPARZA (Drug) $139,743
- TALZENNA (Drug) $131,230
- Erleada (Drug) $130,445
- PROVENGE (Drug) $124,016
- Xofigo (Drug) $122,375
- Xtandi (Drug) $100,221
- ERLEADA (Drug) $75,998
- ORGOVYX (Drug) $62,410
- XGEVA (Biological) $50,699
- PLUVICTO (Drug) $44,637
- Cysview (Drug) $44,144
- ELIGARD (Drug) $40,145
- KEYTRUDA (Biological) $34,746
- SUTENT (Drug) $27,211
- NOCDURNA (Drug) $24,633
- SpaceOAR (Device) $22,981
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in Myrtle Beach
Dr. William Bogache, Md, MD
Urology — Payments: $82,917
Urology $82,917
Dr. Abhishek Srivastava, M.d, M.D
Urology — Payments: $31,006
Urology $31,006
Dr. Brian Roberts, Md, MD
Urology — Payments: $19,149
Urology $19,149
Dr. Richard Young, Dr, DR
Urology — Payments: $11,015
Urology $11,015
Dr. Kenneth Krzyzaniak, Md, MD
Urology — Payments: $8,180
Urology $8,180
Dr. Lauren Cooley, M.d, Ph.d, M.D, PH.D
Urology — Payments: $4,468
Urology $4,468